ONCOTYPE DXBreast Cancer Genomic Recurrence Score

Patient & Genomic Data

Recurrence Score (RS)

Points

Patient Age

Years

TAILORx Context

Adjuvant chemotherapy benefit in node-negative patients is primarily determined by the Recurrence Score. For patients ≤ 50 years, even intermediate scores may warrant chemotherapy consideration due to potential ovarian suppression effects or higher intrinsic risk.

Therapeutic Outlook

18

Chemo Benefit

Intermediate recurrence score. Minimal chemotherapy benefit in patients ≥ 50 years (TAILORx).

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

Early-stage (Stage I-II), Hormone Receptor (HR)-positive, HER2-negative invasive breast cancer.

Node-negative disease (TAILORx paradigm) or 1-3 positive lymph nodes (RxPONDER paradigm).

Used exclusively to determine if the addition of adjuvant chemotherapy to endocrine therapy provides an overall survival or disease-free survival benefit.

How it Works

The 21-Gene Panel

The assay uses RT-PCR on formalin-fixed, paraffin-embedded (FFPE) tumor tissue to measure the expression of 16 cancer-related genes (grouped by proliferation, invasion, HER2, and estrogen pathways) and 5 reference genes. It generates a continuous Recurrence Score (RS) from 0 to 100.

Risk Categories (Post-TAILORx)

Recurrence Score	Risk Category	Chemotherapy Benefit
0 - 25	Low-Intermediate Risk	No chemotherapy benefit in women > 50 years.
26 - 100	High Risk	Significant absolute benefit from chemotherapy across all ages.

Last Comprehensive Review: 2026

ONCOTYPE DXBreast Cancer Genomic Recurrence Score

Patient & Genomic Data

Recurrence Score (RS)

Points

Patient Age

Years

TAILORx Context

Therapeutic Outlook

18

Chemo Benefit

Intermediate recurrence score. Minimal chemotherapy benefit in patients ≥ 50 years (TAILORx).

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

Early-stage (Stage I-II), Hormone Receptor (HR)-positive, HER2-negative invasive breast cancer.

Node-negative disease (TAILORx paradigm) or 1-3 positive lymph nodes (RxPONDER paradigm).

Used exclusively to determine if the addition of adjuvant chemotherapy to endocrine therapy provides an overall survival or disease-free survival benefit.

How it Works

The 21-Gene Panel

Risk Categories (Post-TAILORx)

Recurrence Score	Risk Category	Chemotherapy Benefit
0 - 25	Low-Intermediate Risk	No chemotherapy benefit in women > 50 years.
26 - 100	High Risk	Significant absolute benefit from chemotherapy across all ages.

Last Comprehensive Review: 2026

Oncotype DX Recurrence

Patient & Genomic Data

18

When to Use

Clinical Use

How it Works

The 21-Gene Panel

Risk Categories (Post-TAILORx)

Clinical Pearls

The Pre-Menopausal Nuance (Age ≤ 50)

Node Positive Disease (RxPONDER)

The Evidence

Key References

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx)

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer (RxPONDER)

Related Tools

Recent Journal Updates

Oncotype DX Recurrence

Patient & Genomic Data

18

When to Use

Clinical Use

How it Works

The 21-Gene Panel

Risk Categories (Post-TAILORx)

Clinical Pearls

The Pre-Menopausal Nuance (Age ≤ 50)

Node Positive Disease (RxPONDER)

The Evidence

Key References

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx)

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer (RxPONDER)

Related Tools

Recent Journal Updates